These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31625348)

  • 21. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies.
    Ketterer N; Salles G; Moullet I; Dumontet C; ElJaafari-Corbin A; Tremisi P; Thieblemont C; Durand B; Neidhardt-Berard EM; Samaha H; Rigal D; Coiffier B
    Br J Haematol; 1998 Oct; 103(1):235-42. PubMed ID: 9792315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of the effectiveness of hematopoietic cell mobilization with chemotherapy and filgrastim versus filgrastim alone for autologous transplant in patients with lymphoma.].
    Gutiérrez-Aguirre CH; De la Garza-Salazar F; Cantú-Rodríguez O; González-Llano Ó; Jaime-Pérez JC; Mancias-Guerra C; García-Sepúlveda R; Salazar-Riojas R; Gómez-Almaguer D
    Gac Med Mex; 2016 Oct; 152(Suppl 2):57-65. PubMed ID: 27792717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
    Pocali B; De Simone M; Annunziata M; Palmieri S; D'Amico MR; Copia C; Viola A; Mele G; Schiavone EM; Ferrara F
    Leuk Lymphoma; 2004 Aug; 45(8):1605-9. PubMed ID: 15370212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of the mobilization regimen in lymphoma patients: A retrospective cohort study.
    Sarici A; Erkurt MA; Kuku I; Gok S; Bahcecioglu OF; Bicim S; Berber I; Kaya E; Ozgul M
    Transfus Apher Sci; 2021 Oct; 60(5):103251. PubMed ID: 34419358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
    Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
    J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy.
    Cook G; Marinaki P; Farrell E; Pearson C; Alcorn MJ; Sharp RA; Tansey PJ; Franklin IM
    Leukemia; 1997 Dec; 11 Suppl 5():S35-40. PubMed ID: 9436937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study.
    Han X; Ma L; Zhao L; He X; Liu P; Zhou S; Yang J; Qin Y; Yang S; Yao J; Shi Y
    J Clin Apher; 2012; 27(2):64-74. PubMed ID: 22298390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.
    Giebel S; Sadus-Wojciechowska M; Halaburda K; Drozd-Sokolowska J; Wierzbowska A; Najda J; Mendrek W; Sobczyk-Kruszelnicka M; Nowicki M; Holowiecki J; Czerw T
    Ann Hematol; 2016 Jan; 95(2):263-9. PubMed ID: 26611854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
    Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J
    Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP + G-CSF in patients with pretreated non-Hodgkin's lymphoma.
    Liu JH; Chen CC; Bai LY; Chao SC; Chang MS; Lin JS
    J Chin Med Assoc; 2008 Jun; 71(6):279-85. PubMed ID: 18567557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.
    Heider M; Grass S; Dill V; Rämisch S; Winter C; Verbeek M; Götze KS; Bassermann F; Jilg S
    Transfus Apher Sci; 2021 Oct; 60(5):103197. PubMed ID: 34175195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
    Moskowitz CH; Bertino JR; Glassman JR; Hedrick EE; Hunte S; Coady-Lyons N; Agus DB; Goy A; Jurcic J; Noy A; O'Brien J; Portlock CS; Straus DS; Childs B; Frank R; Yahalom J; Filippa D; Louie D; Nimer SD; Zelenetz AD
    J Clin Oncol; 1999 Dec; 17(12):3776-85. PubMed ID: 10577849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
    Zimmerman TM; Michelson GC; Mick R; Grinblatt DL; Williams SF
    J Clin Apher; 1999; 14(1):31-4. PubMed ID: 10355661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DHAP plus filgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory lymphoma: A single center experience.
    Berber I; Erkurt MA; Kuku I; Kaya E; Bag HG; Nizam I; Koroglu M; Ozgul M
    Transfus Apher Sci; 2016 Feb; 54(1):48-52. PubMed ID: 26809684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
    Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
    J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.